Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Kidney Int. 2011 Feb 2;79(10):1090–1098. doi: 10.1038/ki.2010.544

Figure 7. Role of sphingosine 1-phosphate 1 receptor (S1P1R) agonists in immortalized podocytes in vitro.

Figure 7

(a, b) Total RNA from immortalized podocytes was extracted and subjected to analysis by reverse transcriptase-PCR (RT-PCR) for S1P receptor mRNA expression (a) and sphingosine kinase 1 and 2 (SphK1 and SphK2) mRNA expression (b). (c, d) Total RNA from immortalized podocytes subjected to normal glucose (NG) or high glucose (HG) media for 14 days with or without SEW2871 (n = 5–6 each group) was extracted and subjected to analysis by RT-PCR for tumor necrosis factor-α (TNF-α) mRNA expression (c) and vascular endothelial growth factor (VEGF) mRNA expression (d). Expression of TNF-α and VEGF mRNA was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Open bars, NG; black bars, HG treated with vehicle; and gray bars, HG treated with SEW2871 (1 μmol/l). Data are means ± s.e.m. *P < 0.05, **P < 0.01 compared with NG; +P < 0.05 compared with HG + vehicle.